10/10/2013 - 11:39am

Positioned as the first skin care line in the marketplace to feature full vitamin E is the new Vitamin E Intensive Therapy Bodycare line from derma e.

10/10/2013 - 11:39am

Sales of Hyland’s oral analgesic products are up 23.5% to $15.4 million for the 52 weeks ended Aug. 11 across U.S. multi-outlets, according to IRI. Overall sales trends across the category are down by 1.7%, which suggests that what Hyland’s is doing is right — its products are safe, they work and they aren’t formulated with benzocaine.

10/10/2013 - 11:38am

One subcategory that has really jolted the sales-per-square-inch across analgesic sets is sleep aids. Sales of sleeping remedies, including both liquids and tablets, were up 51.2% to $408 million for the 52 weeks ended Aug. 11 across U.S. multi-outlets, according to IRI data.

10/10/2013 - 11:38am

i-Health’s Estroven has been dialing up sales tracked within feminine pain relievers. The core brand generated $16.2 million within the last 52 weeks ended Aug. 11 across U.S. multi-outlets, according to IRI.

10/10/2013 - 11:38am

Such iconic pain relief brands as McNeil Consumer’s Tylenol and Motrin, and Novartis’ Excedrin, have made their way back to the shelf this fall following a recall-driven hiatus. And the sales have already started to accumulate.

10/10/2013 - 11:38am

There may still be room for substantial growth in multivitamins — like in gummy vitamins.

10/10/2013 - 11:38am

Many of the larger probiotic brands are experiencing significant growth. i-Health’s Culturelle generated $61.6 million in sales on a growth rate of 44.5% for the 52 weeks ended Aug. 11, according to IRI data across U.S. multi-outlets. And sales of Bayer’s Phillips Colon Health were up 18.5% to $58.7 million.

10/10/2013 - 11:38am

Pharmavite launched its latest VMS innovation, Nature Made VitaMelts, earlier this summer, and already the brand ranks No. 12 among one- and two-letter vitamins, according to 52-week sales data as tracked by IRI.

10/10/2013 - 10:55am

A subsidiary of Johnson & Johnson has acquired rights to an experimental drug for hepatitis C from GlaxoSmithKline.